Generate Biomedicines, Inc.
NASDAQ:GENBAsset Management
+$0.13 today
- Market cap
- $1.34B
- Beta
- 0.19
- P/E (TTM)
- -3.5
- EPS (TTM)
- -$4.06
Volume 1.05M
Average 0.55M
GENB EPS (Diluted)
Earnings per share assuming conversion of dilutive securities such as options and convertible instruments.
Generate Biomedicines, Inc.NASDAQ: GENB
EPS (Diluted) · Q1 FY2026 · quarter ended Mar 2026
EPS (Diluted) of -$0.54 in Q1 FY2026
Q1 FY2026 EPS (Diluted) was -$0.54.
What to watch
Whether EPS (Diluted) reaches the consensus estimate from 4 analysts of -$2.56 (+48.7%) for the fiscal year ending Dec 2026, a step up from the -196.4% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$0.54— QoQ
- Last fiscal yearDec 2025
- -$4.98-196.4% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | — | — | — |
| 1 year | -196.4% | +48.7% | +245.1 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EPS (Diluted) history
USD · from the income statement
- Latest · FY2025
- (4.98) USD
- Year-over-year change
- -196.4%
| Period | Period end | EPS (Diluted) | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (4.98) | -196.4% |
| FY2024 | 2024-12-31 | (1.68) | — |
EPS (Diluted) vs competitors
How GENB compares with its peers on the latest reported figures
- GENB's FY2025 EPS (Diluted) of -$4.98 is the 3rd highest of the 5 companies compared; the peer median is -$4.61.
- Its year-over-year change of -196.4% is the 4th highest of 5, against a peer median of -48.7%.
| Company | Period | LTM | YoY | 3-year CAGR |
|---|---|---|---|---|
| LTM Sep 2026 | -$0.48 | +17.2% | — | |
| LTM Mar 2026 | -$0.83 | +9.8% | — | |
GENBGenerate Biomedicines, Inc. | FY2025 | -$4.98 | -196.4% | — |
| LTM Mar 2026 | -$8.39 | -107.2% | — | |
| LTM Mar 2026 | -$307.72 | -936.1% | — | |
| Peer median (excluding GENB) | -$4.61 | -48.7% | — | |
Competitors are the stored peer set for GENB. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|
| Revenue | 20.46M | 31.89M |
| Cost of Revenue | 0 | 0 |
| Gross Profit | 20.46M | 31.89M |
| Gross Margin | 100.0% | 100.0% |
| Research & Development | 175.31M | 224.7M |
| Selling, General & Admin | 42.09M | 42.26M |
| Operating Expenses | 217.4M | 266.96M |
| Depreciation & Amortization | 15.35M | 13.18M |
| EBITDA | (163.71M) | (208.49M) |
| EBITDA Margin | -800.2% | -653.7% |
| Operating Income | (196.94M) | (235.07M) |
| Operating Margin | -962.6% | -737.0% |
| Interest Income | 18.12M | 13.66M |
| Interest Expense | 2.12M | 1.14M |
| Other Income / Expenses | 15.77M | 12.26M |
| Income Before Tax | (181.17M) | (222.8M) |
| Pre-Tax Margin | -885.5% | -698.6% |
| Income Tax Expense | 212K | 163K |
| Net Income | (173.77M) | (203.15M) |
| Net Margin | -849.4% | -637.0% |
| EPS (Basic) | (1.68) | (4.98) |
| EPS (Diluted) | (1.68) | (4.98) |
| Weighted Avg Shares | 127.45M | 50.09M |
| Weighted Avg Shares (Diluted) | 127.45M | 50.09M |
Generate Biomedicines, Inc.
NASDAQ:GENB
Intrinsic Alpha fair value
Locked
Current Price
$10.38
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.